GHRP-2 vs Ipamorelin: Which Growth Hormone Secretagogue Is Right for You?

What Are GHRP-2 and Ipamorelin, and How Do They Work?

Both peptides bind the growth hormone secretagogue receptor 1a (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons, mimicking ghrelin to provoke a pulse of endogenous GH release. The critical difference is receptor selectivity. GHRP-2 (pralmorelin) is a first-generation hexapeptide that binds GHS-R1a with high affinity but also engages secondary receptors, producing off-target effects on cortisol, prolactin, and hunger. Ipamorelin is a third-generation pentapeptide engineered for tighter selectivity, leaving cortisol and prolactin pathways largely untouched.

A 1999 dose-finding study in healthy adults showed that intravenous GHRP-2 at 1 mcg/kg produced a mean peak GH of roughly 50 ng/mL within 15 minutes, compared with roughly 10 ng/mL at baseline [1]. The same research confirmed concurrent ACTH and cortisol elevations, confirming the off-target adrenal stimulation that distinguishes GHRP-2 from newer secretagogues.

Ipamorelin's selectivity was characterized in a landmark 1998 study by Raun et al., which reported that ipamorelin stimulated GH release in rats and pigs without any measurable increase in ACTH, cortisol, or prolactin at doses up to 500 mcg/kg, a selectivity profile not seen in GHRP-2 or GHRP-6 [2]. The authors called ipamorelin "the first truly selective GH secretagogue," language that still holds clinical weight.

Because neither peptide provides growth hormone releasing hormone (GHRH) activity, stacking either with a GHRH analog such as CJC-1295 or sermorelin amplifies the GH pulse through a complementary mechanism. The pituitary responds to simultaneous GHRH-receptor and GHS-R1a stimulation with a synergistic release far exceeding either agent alone.

GHRP-2 vs Ipamorelin: Head-to-Head on the Metrics That Matter

The two peptides share a pharmacological category but diverge on nearly every practical clinical variable. GHRP-2 delivers a more forceful acute GH spike, which may be useful in short-term applications such as post-surgical recovery or severe catabolic states. Ipamorelin delivers a more moderate, sustained-feeling response that fits chronic wellness, anti-aging, and sleep-quality protocols with a cleaner safety margin.

GH pulse amplitude. GHRP-2 consistently outperforms ipamorelin for raw GH elevation in head-to-head animal models. A comparative pharmacology study found GHRP-2 produced peak GH values roughly two to three times higher than equimolar doses of ipamorelin in rodents [3]. Bigger is not always better here: supraphysiologic GH pulses increase IGF-1 disproportionately and carry a higher risk of insulin resistance and edema.

Cortisol and adrenal load. This is the clearest clinical differentiator. GHRP-2 activates the hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol 35 to 50% above baseline in human studies [4]. Sustained cortisol elevation impairs sleep architecture, raises fasting glucose, and can blunt immune function. Ipamorelin does not produce this effect at clinical doses [2].

Appetite. Ghrelin is the primary appetite-signaling hormone, so any ghrelin-receptor agonist may increase hunger. GHRP-2's strong GHS-R1a activation reliably increases caloric intake in rodent and human models [5]. Ipamorelin's partial selectivity produces significantly less appetite stimulation, which matters for patients on calorie-controlled protocols or those prone to binge eating.

Half-life and dosing windows. Both peptides have short plasma half-lives of roughly 15 to 30 minutes, requiring subcutaneous injection two to three times daily for sustained effect. Dosing just before sleep takes advantage of natural nocturnal GH pulsatility. Fasting for 60 to 90 minutes before injection reduces the blunting effect of insulin and free fatty acids on GH release.

IGF-1 response. Because IGF-1 is the downstream mediator of most GH anabolic effects, the clinical outcome users seek, the relevant question is how much each peptide raises serum IGF-1 over weeks of use. A 2003 study in GH-deficient children treated with the related peptide GHRP-6 (structurally similar to GHRP-2) showed IGF-1 normalized after 6 months of three-times-daily dosing [6]. Ipamorelin produces a more modest IGF-1 elevation in proportion to its smaller GH pulse, which may reduce long-term IGF-1-related concerns.

How BPC-157 and TB-500 Fit Into a Peptide Stack

GHRP-2 and ipamorelin address GH secretion. BPC-157 and TB-500 address tissue repair through entirely different pathways, making them logical stack companions rather than competitors.

BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide fragment of a gastric protein found in human gastric juice. It promotes angiogenesis, upregulates growth factor receptors, and modulates nitric oxide production. A 2016 rodent study published in the Journal of Physiology and Pharmacology showed BPC-157 accelerated healing of transected Achilles tendon by increasing vascular ingrowth and collagen organization compared with saline controls [7]. Typical research dosing is 200 to 400 mcg subcutaneously or intramuscularly once or twice daily near the injury site.

TB-500 (thymosin beta-4 fragment) promotes actin polymerization, reduces inflammation, and increases cell migration into wound beds. A 2010 paper in Annals of the New York Academy of Sciences demonstrated thymosin beta-4 reduced infarct size and improved cardiac function in rat myocardial infarction models, pointing to systemic cytoprotective effects beyond simple wound healing [8]. Research dosing typically runs 2 to 2.5 mg twice weekly for 4 to 6 weeks, followed by a maintenance phase of 2 mg monthly.

BPC-157 vs TB-500 for tendon and ligament injuries. BPC-157 shows stronger evidence for gut lining repair, tendon-to-bone healing, and joint inflammation. TB-500 shows broader systemic anti-inflammatory and cardiac protective data. For acute tendon tears or chronic joint pain, BPC-157 is often the first-line peptide choice. For systemic recovery after overtraining or after surgery involving multiple tissue types, TB-500 may offer wider benefit. Combining both at half their usual doses has become a common clinical approach, though controlled human trial data comparing the combination against monotherapy are absent.

IGF-1 vs IGF-1 LR3: Choosing the Right Downstream Signal

IGF-1 (insulin-like growth factor 1) and its long-arginine3 analog IGF-1 LR3 both bind IGF-1 receptors and drive cellular growth, protein synthesis, and glucose uptake, but they differ in a property that changes everything clinically: binding protein affinity.

Native IGF-1 circulates mostly bound to IGF binding proteins (IGFBPs), particularly IGFBP-3, which extend its half-life to roughly 12 to 15 hours but also limit free bioavailability. IGF-1 LR3 was engineered with an arginine substitution at position 3 that reduces IGFBP binding by approximately 99%, leaving it almost entirely free in circulation [9]. The result is a plasma half-life of 20 to 30 hours for IGF-1 LR3 versus less than 10 minutes for native IGF-1 injected exogenously.

That extended free-activity window is a double-edged sword. IGF-1 LR3 produces more sustained anabolic signaling per injection, which explains its use in research on muscle wasting and GH deficiency syndromes. The same sustained signaling raises theoretical concerns about mitogenic effects, since IGF-1 receptors are expressed on many tumor cell lines [10]. The National Cancer Institute's SEER database has linked chronically elevated serum IGF-1 in observational studies to modestly increased prostate and colorectal cancer risk, though causality has not been established in interventional trials [10].

For clinical wellness use, raising IGF-1 through a GHRH analog plus a secretagogue such as ipamorelin gives the body's own IGFBP-3 regulatory system a chance to buffer the signal. Direct injection of IGF-1 LR3 bypasses that buffer entirely. Most conservative protocols favor the indirect route, using peptide secretagogues to bring IGF-1 to the upper quartile of the age-adjusted reference range (typically 200 to 300 ng/mL for adults aged 30, 50) rather than supraphysiologic levels above 400 ng/mL.

Semax vs Selank: Two Nootropic Peptides With Different Targets

Semax and Selank are both synthetic peptides developed in Russia, both administered intranasally, and both studied primarily for cognitive and mood applications, but they operate through mechanistically distinct pathways and suit different clinical presentations.

Semax is a synthetic heptapeptide analog of ACTH(4-7). It increases brain-derived neurotrophic factor (BDNF), upregulates NGF, and enhances dopaminergic and serotonergic signaling. A 2011 Russian clinical study (N=50) showed intranasal Semax 0.1% at 400 mcg twice daily over 14 days significantly improved attention, short-term memory, and processing speed in patients recovering from ischemic stroke compared with standard rehabilitation alone [11]. The effect on BDNF is particularly relevant for neuroplasticity and recovery from brain injury or chronic stress.

Selank is a synthetic heptapeptide analog of tuftsin with an added tripeptide sequence for stability. Its primary mechanism involves modulation of GABAergic transmission, reduction in anxiety-related behavior, and mild normalization of serotonin and dopamine metabolism. A 2008 clinical trial published in Bulletin of Experimental Biology and Medicine (N=62) found intranasal Selank at 400 mcg three times daily reduced anxiety scores on the Hamilton Anxiety Rating Scale by an average of 11.2 points over 28 days, comparable to the benzodiazepine control without sedation or dependence risk [12].

Clinically, the choice between them maps to the presenting symptom cluster. Patients reporting poor focus, slow recovery from mental effort, or post-COVID cognitive fog tend to respond better to Semax. Patients with anxiety, stress-driven insomnia, or emotional lability are more likely to benefit from Selank. Both peptides are used at 400 to 900 mcg intranasal doses, one to two times daily. Cycling every 30 days is standard practice, as receptor sensitivity data in rodent models suggest tachyphylaxis may develop with continuous administration beyond 4 to 6 weeks [12].

Epitalon vs TB-500 for Longevity Protocols

Epitalon (epithalon) is a tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide epithalamin. Its primary proposed mechanism in longevity research is telomerase activation. A 2003 study by Khavinson et al. demonstrated that Epitalon induced telomerase activity in human somatic cells in vitro and extended the replicative lifespan of cell cultures compared with untreated controls [13]. Separately, a Russian cohort study following 266 elderly patients (mean age 74) over 6 years found that those receiving annual Epithalamin injections had a 28% lower mortality rate and fewer cardiovascular events than the control group [13], though blinding and allocation concealment in that study limit the strength of the conclusion.

TB-500's longevity case rests on different ground: reduced fibrosis, accelerated repair of age-related tissue damage, and cardioprotection. The thymosin beta-4 peptide has been studied in cardiac models showing reduction in fibrotic remodeling post-infarction [8]. Age-related tissue stiffness and fibrosis are now recognized contributors to the aging phenotype, making TB-500's mechanism at least theoretically relevant to longevity beyond pure injury recovery.

How to choose between them for an anti-aging protocol. Epitalon targets replicative senescence at the cellular level via telomere biology. TB-500 targets structural tissue integrity at the organ level via cytoskeletal remodeling. A longevity-focused protocol might include both, using Epitalon at 10 mg daily for 10 days, two to three cycles per year, alongside TB-500 at 2 mg twice weekly during physically demanding training blocks. No head-to-head longevity trial comparing the two exists in published human data as of mid-2025.

Dosing, Timing, and Stacking: A Clinical Framework

Peptide stacking requires matching mechanisms to patient goals and managing injection burden. The following table summarizes evidence-based research dosing for each peptide discussed in this article. All doses below reflect research literature. None have FDA approval for these uses, and prescribing decisions require physician oversight.

| Peptide | Typical Research Dose | Frequency | Route | Primary Target | |---|---|---|---|---| | GHRP-2 | 100 to 300 mcg | 2, 3x daily | Subcutaneous | GH pulse (aggressive) | | Ipamorelin | 200 to 300 mcg | 2, 3x daily | Subcutaneous | GH pulse (selective) | | CJC-1295 (no DAC) | 100 to 300 mcg | 2, 3x daily | Subcutaneous | GHRH amplification | | BPC-157 | 200 to 400 mcg | 1, 2x daily | SC or IM | Tissue repair / gut healing | | TB-500 | 2 to 2.5 mg | 2x weekly x 4, 6 wk | Subcutaneous | Systemic anti-inflammatory | | IGF-1 LR3 | 20 to 60 mcg | Daily x 4 wk, then off | Subcutaneous | Direct IGF-1 receptor activation | | Semax | 400 to 900 mcg | 1, 2x daily | Intranasal | BDNF, cognition, neuroprotection | | Selank | 400 to 900 mcg | 1, 2x daily | Intranasal | Anxiolysis, GABAergic modulation | | Epitalon | 10 mg | Daily x 10 days, 2, 3 cycles/year | Subcutaneous or IV | Telomerase activation, senescence |

Injection timing matters. GH secretagogues such as ipamorelin and GHRP-2 should be administered in a fasted state, ideally 90 minutes after the last meal and 30 minutes before sleep to capitalize on the physiologic nocturnal GH surge. Insulin blunts GH release, so carbohydrate intake close to injection significantly reduces efficacy [1].

Monitoring is non-negotiable. At baseline: serum IGF-1, fasting insulin, HbA1c, prolactin, cortisol (morning draw), and a full metabolic panel. At 8 to 12 weeks: repeat IGF-1, fasting glucose, and cortisol if using GHRP-2. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults states that IGF-1 should be maintained within the age-adjusted and sex-adjusted reference range and that dosing should be titrated to normalize, not maximize, serum IGF-1 levels [14].

Regulatory Status and Access in 2025

Neither GHRP-2 nor ipamorelin holds FDA approval for any indication. Ipamorelin and several companion peptides appeared on the FDA's list of bulk drug substances that may not be compounded under Section 503A and 503B of the Food, Drug, and Cosmetic Act, a designation that restricted licensed compounding pharmacies from dispensing them beginning in 2024 [15]. Patients who had active compounded ipamorelin prescriptions were affected directly.

GHRP-2 has not appeared on the same banned-compounding list as of mid-2025, though its status remains subject to FDA review. BPC-157, TB-500 (thymosin beta-4 synthetic), Selank, Semax, and Epitalon are not FDA-approved for any use and exist in US commerce primarily as research chemicals.

Patients seeking any of these peptides through a licensed telehealth provider should confirm that the prescribing physician is working with a 503B outsourcing facility or can document a valid compounding pathway under current FDA guidance. Self-sourcing from unregulated vendors carries substantial risks of contamination, incorrect concentration, and absence of sterility testing.

The FDA's 2024 guidance document on compounding and the 503A nominee list can be reviewed directly on the FDA website [15]. Physicians supervising peptide therapy protocols should confirm current regulatory standing before initiating any prescription.